Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05866757 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Discontinuation Study

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Sep 2026 to Jul 2027
    • Study completion date: Sep 2028 to Jul 2028
    v5
  2. Primary completion date: Aug 2025 to Sep 2026
    • Study completion date: Aug 2025 to Sep 2028
    • Site contact updated
    • Study description shortened, about 1 word
    v4
  3. Site details revisedv3
  4. Trial status: Not Yet Recruiting to Recruitingv2 Show 7 more changesShow less
    • Primary and study completion dates: May 2025 to Aug 2025
    • Start date changed from estimate of May 2023 to Aug 28, 2023
    • Eligibility criteria expanded, about 76 words
    • Secondary endpoints revised (4)
    • Study description expanded, about 22 words
    • Site details revised
    • Study title shortened, about 1 word
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
An interventional, non-randomised study to assess the risk of progression after discontinuation of maintenance therapy in sustained MRD negative complete remission by flow cytometry MM patients without high-risk features who have completed at least two years of maintenance therapy or who have discontinued maintenance due to side effects. The primary endpoint is to assess the rates of sustained MRD negativity by NGF in the bone marrow at 12 months after discontinuation of maintenance therapy.
Trial Details
NCT Number NCT05866757
Lead Sponsor University College Cork
Collaborators: Cancer Research@UCC
Conditions
(from sponsor)		 Multiple Myeloma, Cancer, Hematologic Cancer
Related terms Hematologic Neoplasms, Multiple Myeloma, Neoplasms
Enrollment 70 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov